Premium
Studies on the effect of short‐term oral dihydroergotamine and troxerutin in patients with varicose veins
Author(s) -
SchullerPetrovic Sanja,
Wolzt Michael,
Böhler Kornelia,
Jilma Bernd,
Eichler HansGeorg
Publication year - 1994
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1994.160
Subject(s) - dihydroergotamine , varicose veins , medicine , term (time) , surgery , migraine , physics , quantum mechanics
Objective To evaluate the clinical efficacy and pharmacologic effects of dihydroergotamine and troxerutin on varicose veins. Methods A double‐blind, randomized, placebo‐controlled parallel‐group study was conducted in 53 patients with primary varicose veins. Patients received either a fixed combination of 3 mg dihydroergotamine and 300 mg troxerutin three times a day or placebo for 3 weeks. Symptomatic improvement was assessed by a self‐assessment score, venocontracting effects on a varicose vein were quantified by the venous compliance technique (VCT), and changes in venous dysfunction were measured by digital photoplethysmography (DPPG). Results A significant reduction (p < 0.01) of subjective symptoms was observed in both groups. Results from VCT and DPPG after the therapy with dihydroergotamine and troxerutin or placebo were not significantly different (p > 0.05) from pretreatment values. Furthermore, no significant intergroup difference was observed when the before‐ and after‐therapy differences of values of the self‐assessment scores (VCT and DPPG) were compared. Conclusion In our study, 3 weeks of treatment with a fixed drug combination of 3 mg dihydroergotamine plus 300 mg troxerutin three times a day had no measurable effect compared with placebo on any of the evaluated end points. Clinical Pharmacology and Therapeutics (1994) 56, 452–459; doi: 10.1038/clpt.1994.160